Journal Article

Low expression of Mel-18 predicts poor prognosis in patients with breast cancer

B.-H. Guo, X. Zhang, H.-Z. Zhang, H.-L. Lin, Y. Feng, J.-Y. Shao, W.-L. Huang, H.-F. Kung and M.-S. Zeng

in Annals of Oncology

Published on behalf of European Society for Medical Oncology

Volume 21, issue 12, pages 2361-2369
Published in print December 2010 | ISSN: 0923-7534
Published online May 2010 | e-ISSN: 1569-8041 | DOI: http://dx.doi.org/10.1093/annonc/mdq241
Low expression of Mel-18 predicts poor prognosis in patients with breast cancer

Show Summary Details

Preview

Background: Our previous study suggested that melanoma nuclear protein 18 (Mel-18) acted as a tumor suppressor in human breast cancer. This study was designed to investigate the clinical and prognostic significance of Mel-18 in breast cancer patients.

Patients and methods: Mel-18 was detected by immunohistochemistry in paraffin-embedded tissues from 287 breast cancer patients, of which 287 were from primary cancer sites, 63 from matched adjacent noncancerous sites, and 35 from metastatic lymph nodes. Differences in Mel-18 expression and clinical characteristics were compared by χ2 test. Prognostic outcomes correlated with Mel-18 were examined using Kaplan–Meier analysis and Cox proportional hazards model.

Results: The decreased Mel-18 expression is incremental depending upon the magnitude of cancer progression (P < 0.001). Mel-18 was conversely correlated with the pathological classifications (P < 0.001 for T, N, and M classifications, respectively), clinical staging (P < 0.001), and progesterone receptor (P = 0.030). Furthermore, patients with higher level of Mel-18 showed prolonged overall survivals (P < 0.001). The diminished Mel-18 expression may be a risk factor for the patients’ survival (P < 0.001).

Conclusions: Lower Mel-18 expression is correlated with advanced clinicopathologic classifications and a poor overall survival in breast cancer patients. These findings suggest that Mel-18 may serve as a useful marker in prognostic evaluation for patients.

Keywords: breast cancer; Mel-18; Bmi-1; Polycomb group proteins

Journal Article.  4471 words.  Illustrated.

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.